NASDAQ:SYBX

Synlogic Stock Forecast, Price & News

$3.18

-0.08 (-2.45 %)

(As of 07/23/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.05

▼

$3.28

50-Day Range

$3.18

▼

$4.39

52-Week Range

$1.78

▼

$5.11

Volume425,484 shs

Average Volume188,400 shs

Market Capitalization$166.54 million

P/E RatioN/A

Dividend YieldN/A

Beta1.95

30 days | 90 days | 365 days | Advanced Chart

Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.

About Synlogic

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with Ginkgo Bioworks for the development of synthetic biotic medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Synlogic Publishes Papers in Nature Journals Demonstrating Proof-of-Mechanism and Potential of Synthetic Biotic Platform for the Treatment of Phenylketonuria (PKU)
July 22, 2021 | finance.yahoo.com

ACAD Jan 2023 25.000 put
July 21, 2021 | ca.finance.yahoo.com

Synlogic, Inc. (NASDAQ:SYBX) Short Interest Up 26.6% in June
July 19, 2021 | americanbankingnews.com

Synlogic's (SYBX) Begins Phase I Study for PKU Treatment - Yahoo Finance
July 17, 2021 | finance.yahoo.com

Synlogic's (SYBX) Begins Phase I Study for PKU Treatment - Nasdaq
July 16, 2021 | nasdaq.com

Synlogic Begins Phase 1 Trial for Phenylketonuria Treatment
July 15, 2021 | marketwatch.com

Synlogic's (SYBX) Buy Rating Reiterated at HC Wainwright
July 15, 2021 | americanbankingnews.com

Synlogic Announces Initiation of Phase 1 Study of SYNB1934, a Next-Generation Strain for the Treatment of Phenylketonuria (PKU)
July 15, 2021 | finance.yahoo.com

Synlogic (NASDAQ:SYBX) Now Covered by Analysts at Chardan Capital
July 10, 2021 | americanbankingnews.com

Synlogic, Inc. (NASDAQ:SYBX) Given Consensus Recommendation of "Buy" by Analysts
July 3, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYBX
Previous Symbol
CUSIPN/A
CIK1527599
Webwww.synlogictx.com
Phone617-401-9975
Employees72
Year FoundedN/A

Sales & Book Value

Annual Sales$550,000.00
Price / Sales302.79
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.31 per share
Price / Book0.96

Profitability

EPS (Most Recent Fiscal Year)($1.65)
Net Income$-59,170,000.00
Net MarginsN/A
Return on Equity-48.97%
Return on Assets-39.72%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares52,370,000
Market Cap$166.54 million
Next Earnings Date8/5/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.64 out of 5 stars

Medical Sector

408th out of 2,215 stocks

Pharmaceutical Preparations Industry

193rd out of 867 stocks

3.4 Analyst's Opinion

Consensus Rating
Synlogic has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.82, Synlogic has a forecasted upside of 240.1% from its current price of $3.18.
Amount of Analyst Coverage
Synlogic has only been the subject of 4 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Synlogic has received 307 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Synlogic has received 253 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Synlogic has received 54.82% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Synlogic and other stocks. Vote “Outperform” if you believe SYBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SYBX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Synlogic does not currently pay a dividend.
Dividend Growth
Synlogic does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Synlogic insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 17.95% of the stock of Synlogic is held by insiders.
Percentage Held by Institutions
35.12% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Synlogic are expected to grow in the coming year, from ($1.28) to ($1.21) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Synlogic is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Synlogic is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Synlogic has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Synlogic (NASDAQ:SYBX) Frequently Asked Questions

Is Synlogic a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic or view top-rated stocks.

What stocks does MarketBeat like better than Synlogic?

Wall Street analysts have given Synlogic a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Synlogic wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Synlogic?

Synlogic saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 558,500 shares, an increase of 26.6% from the June 15th total of 441,300 shares. Based on an average trading volume of 421,000 shares, the days-to-cover ratio is currently 1.3 days. Approximately 1.5% of the company's shares are short sold.
View Synlogic's Short Interest.

When is Synlogic's next earnings date?

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Synlogic.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) released its earnings results on Thursday, May, 13th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.39) by $0.03.
View Synlogic's earnings history.

How has Synlogic's stock been impacted by Coronavirus?

Synlogic's stock was trading at $1.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SYBX stock has increased by 106.5% and is now trading at $3.18.
View which stocks have been most impacted by COVID-19.

When did Synlogic's stock split? How did Synlogic's stock split work?

Synlogic shares reverse split on the morning of Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SYBX?

5 brokerages have issued 12-month target prices for Synlogic's stock. Their forecasts range from $3.26 to $15.00. On average, they anticipate Synlogic's stock price to reach $10.82 in the next twelve months. This suggests a possible upside of 240.1% from the stock's current price.
View analysts' price targets for Synlogic or view top-rated stocks among Wall Street analysts.

Who are Synlogic's key executives?

Synlogic's management team includes the following people:

Dr. Aoife M. Brennan M.D., MB, BCh, BAO, MMSc, Pres, CEO & Director (Age 45, Pay $811.3k)
Mr. Antoine Awad, Chief Operating Officer (Age 41, Pay $518.42k)
Dr. Richard J. Riese M.D., Ph.D., Chief Medical Officer (Age 58, Pay $571.32k)
Dr. Timothy K. Lu, Co-Founder
Dr. James J. Collins, Co-Founder (Age 55)
Mr. Gregg D. Beloff, Interim Chief Financial Officer (Age 53)
Dr. David L. Hava, Chief Scientific Officer (Age 46)
Dr. Elizabeth Wolffe, Head of Investor Relations & Corp. Communications
Mr. Daniel Rosan, Sr. VP, Head of Fin. & Investor Relations
Mr. Michael Conlon, VP of Corp. Devel.

Who are some of Synlogic's key competitors?

Some companies that are related to Synlogic include Karyopharm Therapeutics (KPTI), Praxis Precision Medicines (PRAX), Affimed (AFMD), ORIC Pharmaceuticals (ORIC), BioXcel Therapeutics (BTAI), Chimerix (CMRX), PyroGenesis Canada (PYR), Cara Therapeutics (CARA), Eagle Pharmaceuticals (EGRX), Zomedica (ZOM), Albireo Pharma (ALBO), Evolus (EOLS), Verastem (VSTM), Marinus Pharmaceuticals (MRNS) and Chinook Therapeutics (KDNY).
View all of SYBX's competitors.

What other stocks do shareholders of Synlogic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $3.18.

How much money does Synlogic make?

Synlogic has a market capitalization of $166.54 million and generates $550,000.00 in revenue each year. The biotechnology company earns $-59,170,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

How many employees does Synlogic have?

Synlogic employs 72 workers across the globe.

What is Synlogic's official website?

The official website for Synlogic is www.synlogictx.com.

Where are Synlogic's headquarters?

Synlogic is headquartered at 301 Binney St. Suite 402, Cambridge MA, 02142.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]

This page was last updated on 7/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here